Akebia and Keryx Combine to Fight Chronic Kidney Disease
Akebia Therapeutics and Keryx Biopharmaceuticals each saw their shares take a dive on Thursday following news that these two companies had agreed upon a merger.
All Work
Chris Lange
Why Rite Aid Earnings Are Good Enough
Rite Aid released its fiscal first-quarter financial results after the markets closed on Wednesday, and shares ticked up early Thursday.
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday started out as a positive day for the broad U.S. markets, but ultimately ended down. Crude oil was pushed much higher in the session, for its second day in a row. The S&P…
Social Media Stocks See Short Sellers Up the Ante
The June 15 short interest data have been compared with the previous report. Short interest in most of these selected social media stocks increased for this settlement date.
Short Sellers Can’t Make Up Their Minds on Major Oil
The June 15 short interest data have been compared with the previous figures, and short interest in these selected big oil stocks was mixed.
Are Major Banks Signalling Optimism With Short Interest Report?
The June 15 short interest data have been compared with the previous figures, and short interest in these selected big bank stocks was lower.
Short Sellers Hike Bets in Major Pharma Stocks
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Short Sellers Grow More Selective on Cybersecurity Stocks
The June 15 short interest data have been compared with the previous figures, and short interest moves in these selected cybersecurity stocks were mixed.
Pain Therapeutics Shares Reeling After FDA Vote
Pain Therapeutics shares were destroyed on Wednesday after a vote from the FDA was announced.
Why the US Could Lose Big If Trump Imposes Auto Tariffs
Trade wars ultimately hurt all parties involved in one way or another, and with the U.S. president threatening heavy tariffs on imported vehicles, U.S. automakers might be getting the worst deal.
Cara Therapeutics Wins Big With Abdominal Pain Trial
Cara Therapeutics shares made a solid gain on Wednesday after the biotech announced positive results from a midstage trial.
Lovesac Enters the Market With a Bang
The Lovesac Co. (NASDAQ: LOVE) entered the market with a bang on Wednesday in its initial public offering (IPO). The stock entered the market at $25 per share, after having priced at $16. The…
Why Summit Therapeutics Was Crushed
Summit Therapeutics is another biopharma company that is paying the price on Wednesday.
Is Aquinox Pharmaceuticals Done?
Aquinox Pharmaceuticals saw its shares crash on Wednesday after the firm gave a disappointing update for a late-stage trial.
Major Semiconductors Scare Off Short Sellers
The June 15 short interest data have been compared with the previous report. Short interest in most of these selected semiconductor stocks decreased.
Are Pinnacle Foods Shareholders Getting Enough in the Buyout?
Pinnacle Foods shares dropped early on Wednesday after it was announced that the company would be acquired by Conagra Brands.
Short Sellers Run for Cover From Major Biotechs
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was a positive day for the broad U.S. markets with each of the major exchanges recovering, if only slightly, from Monday. Crude oil was pushed much higher in the session, retreating over $70.…
Akamai’s Cloud Facing Headwinds and Narrowing Guidance
Akamai Technologies shares dipped on Tuesday after the company announced updated guidance for the coming quarter and the full year in connection with its analyst day.
Can Puma Biotechnology Break In to Europe?
Puma Biotechnology shares were climbing on Tuesday after the company announced that it expects a positive outcome in Europe.